{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36","upperLimit":"69","value":"53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Anti-tumor responses were analyzed descriptively and summarized in tabular format. Ninety percent confidence intervals for the percentage of subjects with a confirmed anti-tumor response were constructed using the method proposed by Duffy-Santner.\n\nComplete response defined as: no evidence of M-protein on immunofixation of serum and/or urine AND less than 5% plasma cells in the bone marrow biopsy.\n\nPartial response defined as: 50 to 99% decrease in M-protein on serum and/or urine protein electrophoresis.","dispersionType":"90% Confidence Interval","groups":[{"description":"Bort, Dex, and Dox with ALCAR: Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long","id":"OG000","title":"Bort, Dex, and Dox With ALCAR"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every 21 days, up to 24 weeks","title":"Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR","type":"PRIMARY","unitOfMeasure":"percentage of participants"}